$MBX News

MBX Biosciences to Participate in Upcoming November Investor Conferences

Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84

Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?

MBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257%

Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150

MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)

MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

MBX Biosciences to Participate in Upcoming Investor Conferences

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating Once-Weekly Canvuparatide For Treatment Of Chronic Hypoparathyroidism

JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target

Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88

MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights

MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) Estimate

Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91

MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth

MBX Biosciences Appoints Steve Hoerter As Chairman And CEO, Succeeding Kent Hawryluk, With John Smither Named Interim CFO, Effective Immediately

How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy?

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript